Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 12, 2024

Primary Completion Date

February 12, 2025

Study Completion Date

July 13, 2025

Conditions
HCC - Hepatocellular Carcinoma
Interventions
DIAGNOSTIC_TEST

TACE

"study was carried out in our setup for two major reasons. One was to decrease reliance on DSA since it is a costly investigation in our medical setups and the facility is not available except for a few centers of excellence which creates issues with treatments plan of patients admitted for treatment using TACE and subsequent follow-up visits to assess the presence or absence of HCC tumors. The mean age of patients in our treatment group was in the early sixties. This is in line with the median age of diagnosis for HCC globally as evidenced by studies done by Mc Glynn et al12 and Konyn et al13. Gender distribution was predominantly male in our study group in line with available literature14. The Child Pugh classification which quantifies severity of chronic liver disease by assessing clinical parameters was used in our study as well15. Since the inclusion criteria and procedural requirement required normal bilirubin levels, all subjects in the study protocol were in Class A16.~The prima"

Trial Locations (1)

55050

PakEmiratesMH, Rawalpindi

All Listed Sponsors
lead

Pak Emirates Military Hospital

OTHER

NCT06602986 - Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter